Sequencing BCMA Myeloma Therapies image

Sequencing BCMA Myeloma Therapies

Apr 11, 2023
01:00PM - 02:00PM EDT
Online Event
Overview

Let's learn together what we know about sequencing BCMA therapies, and what there's left to learn. As more immunotherapies targeting BCMA on cancerous myeloma plasma cells continue to be develop, there is question about which combination of these treatments is most efficacious, and what precautions need to be taken when using such similar targeted therapies. Join Dr. Josh Richter, a myeloma specialist, as he shares information regarding this topic.

Agenda
1:00 PM
Introductions
Audrey Burton-Bethke

Audrey introduces the agenda of the event and featured speaker Dr. Joshua Richter.

1:05 PM
Presentation
Joshua Richter

Dr. Joshua Richter shares about sequencing BCMA therapies.

 

 

1:35 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators
Healthtree contact Audrey Burton-Bethke

Audrey Burton-Bethke

Audrey is a content writer and editor for the HealthTree Foundation.

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Healthtree contact Joshua Richter

Joshua Richter

Multiple Myeloma Specialist

Joshua Richter, MD, is Associate Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical Oncology. He is the director of Multiple Myeloma at the Blavatnik Family- Chelsea Medical Center at Mount Sinai. Dr. Richter treats patients with plasma cell dyscrasias, including multiple myeloma and related diseases such as AL amyloidosis, plasma cell leukemia, and Waldenstrom’s Macroglobulinemia. Dr. Richter has extensive experience with clinical trials focused on novel therapies, including antibody therapy and immunotherapy for a precision medicine approach. He has published extensively on these topics and has been invited to speak regionally, nationally, and also internationally. He has been published in journals such as the New England Journal of Medicine, Blood, and the Journal of Clinical Oncology.